Test Code: CPL

PML-RARA Fusion Gene Screening

Test Methodology:

The test is intended for the quantification of PML-RARA type bcr1 fusion transcripts in bone marrow or peripheral blood samples in a subgroup of acute myeloid leukemia (AML) patients diagnosed with M3 cytomorphology and t(15;17)(q22;q21) translocation, with a breakpoint into PML intron 6 by realtime PCR. The results obtained are intended to be used as an aid to monitor efficacy of treatment in patients undergoing therapy, and for minimal residual disease (MRD) follow-up to monitor disease relapse.

Specimen Required:　

6ml EDTA Blood

Turnaround Time :　

Maximum to 5 days